Cochlear Ltd is primarily active in the healthcare and medical device industries.

The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.

Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.

Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.

Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.

Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.

Analysts currently set an average price target of 265,71 AUD for the Cochlear stock (median: 252,40 AUD), implying +112,8 % versus the latest price. The consensus is based on 19 analyst ratings.

Cochlear Analītiķu cenu mērķi 2026

19 analysts currently rate the Cochlear stock: 9 recommend buying, 9 holding and 1 selling. For 2026, analysts expect Cochlear to generate revenue of 2,33 B AUD and earnings per share of 4,73 AUD.

Cochlear Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the Cochlear share trades at 76,30 EUR (124,86 AUD).

The Cochlear share (COH.AX) is listed on 7 stock exchanges, including: Frankfurt (OC5.F), München (OC5.MU), Düsseldorf (OC5.DU), Hamburg (OC5.HM), SIX (Zürich) (COH.SW), ASX (COH.AX).

Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.

gaidāmā apgrozījums Cochlear ir 2,33 B AUD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa Cochlear ir 310,29 M AUD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

Cochlear cenas un peļņas rādītājs (P/E) pašlaik ir 26,40. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Cochlear akcijas vērtību.

Cochlear cenas un apgrozījuma rādītājs (P/S) pašlaik ir 3,51. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Cochlear akcijas vērtības mērs.

Cochlear Eulerpool kvalitātes rādītājs ir 7/10.

Cochlear ISIN ir AU000000COH5. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

Cochlear WKN ir 898321. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

Cochlear tikeris ir COH.AX. Tikeris tiek izmantots Cochlear akciju tirdzniecībai biržā.

Pēdējo 12 mēnešu laikā Cochlear maksāja dividendes 5,82 AUD apmērā. Tas atbilst aptuveni 4,66 % dividendes ražībai. Nākamajos 12 mēnešos Cochlear plāno maksāt dividendes 6,11 AUD apmērā.

Cochlear pašreizējā dividendu rentabilitāte ir 4,66 %.

Cochlear maksā dividendes, kas tiek sadalītas mēnešos , , , .

Cochlear pēdējo 30 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 6,11 AUD. Tas atbilst dividendes ražībai 4,89 %.

Cochlear tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Cochlear apmērā 2,93 AUD, kas tika izmaksāta , tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija .

Pēdējās dividendes izmaksa notika .

Gadā 2025, Cochlear izmaksāja 4,88 AUD dividendes.

Cochlear dividendes tiek izmaksātas AUD.